Manufacturer of CNS Drugs - Pregabalin, LevodopaCarbidopaTablets, Ketoconazole and Risperidone offered by Centurion Laboratories Private Limited, Vadodara, Gujarat. CYP3A4 inducers exert their effect in a time-dependent manner, and may take at least 2 weeks to reach maximal effect after introduction. It allows continued monitoring of the benefit/risk balance of the medicinal product. Risperidone plus 9-hydroxy-risperidone form the active antipsychotic fraction. For children weighing less than 25 kg, risperidone 0.5 to 2.5 mg/day was given; for children 25 kg or more, doses ranged from 0.5 to 3.5 mg/day. This list is indicative and not exhaustive.Risperidone may antagonise the effect of levodopa and other dopamine agonists. Both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotic medicinal products; these patients were excluded from clinical trials. Subsequently, the dosage can be maintained unchanged, or further individualised, if needed. In placebo-controlled trials with oral risperidone in this population, the incidence of mortality was 4.0 % for risperidone -treated patients compared to 3.1 % for placebo-treated patients. Risperidone 1mg Tablets are available in pack size of 20 tablets. (See also section 4.4)The efficacy of risperidone in the short-term treatment of disruptive behaviours was demonstrated in two double-blind placebo-controlled studies in approximately 240 patients 5 to 12 years of age with a DSM-IV diagnosis of disruptive behaviour disorders (DBD) and borderline intellectual functioning or mild or moderate mental retardation/learning disorder. There are no data available on adverse reactions in breast-feeding infants. Amitriptyline does not affect the pharmacokinetics of risperidone or the active antipsychotic fraction. NAME OF THE MEDICINAL PRODUCT Risperidone Dispersible Tablets 1mg Taj Pharma Risperidone Dispersible Tablets 2mg Taj Pharma 2. Irrespective of treatment, dehydration was an overall risk factor for mortality and should therefore be carefully avoided in elderly patients with dementia.An approximately 3-fold increased risk of cerebrovascular adverse events have been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics. 4.5 Interaction with other medicinal products and other forms of interaction6.6 Special precautions for disposal and other handling9. The name of your medicine is Risperdal 2mg tablets, but it will be referred as Risperdal throughout this leaflet. ● Erythromycin, a moderate CYP3A4 inhibitor and P-gp inhibitor, does not change the pharmacokinetics of risperidone and the active antipsychotic fraction. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain medicines or of conditions such as intestinal obstruction, Reye's syndrome, and brain tumour.Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than adults with normal renal function. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. Therefore, the advantage of breast-feeding should be weighed against the potential risks for the child.As with other drugs that antagonize dopamine D2 receptors, RISPERIDONE elevates prolactin level. Veuillez lire attentivement cette notice avant de prendre ce médicament car elle contient des informations importantes pour vous. For a complete list of all side effects, Risperidone is an antipsychotic that relieves psychotic symptoms in people with schizophrenia or mania and is also used in the treatment of autistic disorder. When the carbamazepine group was excluded in a post-hoc analysis, risperidone combined with lithium or valproate was superior to lithium or valproate alone in the reduction of YMRS total score.The efficacy of risperidone in the treatment of Behavioural and Psychological Symptoms of Dementia (BPSD), which includes behavioural disturbances, such as aggressiveness, agitation, psychosis, activity, and affective disturbances was demonstrated in three double-blind, placebo-controlled studies in 1150 elderly patients with moderate to severe dementia.